Evotec

Valuation Analysis

About the Company

Evotec en bref

Evotec (EVT.DE) is currently trading at 4,54 € with a market capitalization of 703 M €. The 52-week range spans from 4,00 € to 7,84 €; the current price is 42.1% below the yearly high. Year-over-year revenue growth stands at -21.7%.

💰 Dividende

Evotec currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

7 analystes évaluent Evotec (EVT.DE) au consensus : Acheter. L'objectif de cours moyen est de 6,44 €, soit un potentiel de +41.98% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 4,00 € à 10,00 €.

Evotec : la thèse d'investissement en détail

Evotec (EVT.DE) operates in the Healthcare — specifically Drug Manufacturers - Specialty & Generic — and is headquartered in Germany. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Wall Street consensus sits at Buy with an average price target implying roughly 41.98% upside from current levels — analyst sentiment is firmly constructive.

Le scénario baissier

Revenue is contracting at -21.7% year-over-year — until that trend reverses, valuation is exposed to further downgrades. Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders.

Valorisation en contexte

The PEG ratio at 1.43 sits in the reasonable zone — the price tag is roughly aligned with the company's growth profile, neither punishing nor euphoric.

À surveiller

• The price sits in the lower quartile of the 52-week range — value hunters often start scaling in around this zone if fundamentals hold.
• The analyst consensus price target implies 41.98% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price is below both the 50- and 200-day moving averages, with 50d below 200d — a bearish picture (death-cross alignment).

Profil de risque

The data points to market-like volatility.

Trading Data

Related Stocks in the Same Sector

Where can I buy Evotec?

Compare top-rated brokers — low fees, trusted providers, fully regulated.